An interventional study of Branched Chain Amino Acids and Branched Chain Amino Acids in Traumatic Brain Injury, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 6th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2021, is one of 37 with no phase, and was the 43rd registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18–89
VA Office of Research and Development · Sites in United States
Ages 22–65
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 61 across the 46 interventional studies, 91 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
3 of the studies in Brain Injuries, Traumatic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02920788VA Office of Research and DevelopmentMild TBI Assessment & Rehabilitation | 2026-12-31 |
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT04003285VA Office of Research and DevelopmentAllopregnanolone in Chronic Complex Traumatic Brain Injury | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.
Mild traumatic brain injury (mTBI) has impacted over 60% of all OEF/OIF Veterans over the past decade, and over 20% of these Veterans carry a diagnosis of postconcussion syndrome. Arguably the most disabling postconcussion symptoms are sleep-wake and cognitive disturbances. Sleep, cognitive function, and related symptoms often remain impaired >10-15 years following mTBI. Not only are these symptoms themselves exceedingly difficult to live with, but poor sleep and cognition also interfere with ongoing rehabilitation interventions, and prevent reintegration into civilian life and return to gainful employment. Most existing therapies for sleep-wake and cognitive dysfunction following mTBI are merely symptomatic, and they also suffer from low efficacy and/or patient acceptability. Thus, there is an urgent need to identify mechanism-based interventions for sleep and cognitive problems following mTBI, in order to facilitate optimal rehabilitation and functional outcomes.
The study team's long-term goal is to implement a brain-bioactive pharmacological intervention to address sleep and cognitive disturbance in individuals with mTBI. The overall objective of this application, which represents the first step towards this goal, is to test the feasibility and limited efficacy of a highly promising therapy consisting of a dietary supplement, branched chain amino acids (BCAA; i.e., leucine, isoleucine, and valine), to treat sleep disturbances in individuals with mTBI. There is compelling scientific precedent and safety data to support the testing of BCAA therapy in Veterans with mTBI. Preliminary preclinical data has shown that the mechanism of action for BCAA, acting as a precursor to the excitatory neurotransmitter glutamate, restores the balance of excitation to inhibition within the dysfunctional brain circuits for both sleep and cognition in mTBI. With these data, the study team has also meticulously mapped the optimal dosing, duration, and route of administration in mice. Further, the study team now has pilot data from a double-blinded, placebo-controlled study showing that 3 weeks of dietary BCAA supplementation, but not placebo, significantly improved self-reported sleep in Veterans. Other research groups have used dietary BCAA supplementation in humans across multiple conditions at doses up to 60 grams/day and durations up to 12 months with few to no side effects.
The central hypothesis is that BCAA dietary supplementation will improve sleep quality in Veterans with mTBI. As a first step towards testing this hypothesis, herein is proposed a long-term feasibility, acceptability, and limited efficacy study of BCAA's effects on sleep that will be randomized, placebo-controlled, and double-blinded. Veterans with mTBI will be randomly assigned to receive BCAA at 20, 40 or 60 grams/day per oral (PO) or a placebo (n=50 per group) for 12 weeks. Feasibility, acceptability, and limited efficacy outcomes based on sleep (e.g., self-report, continuous actigraphy, and overnight polysomnography) will be assessed.
Results will inform the optimal study methodology and design for a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may be differentially affected by BCAA. This work will aos be used to generate hypotheses on the effect of BCAA on cognition and overall quality of life measures to inform future research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Not be starting another sleep intervention (e.g., positive airway pressure therapy for sleep apnea, sedative-hypnotic medication, or cognitive behavioral therapy for insomnia) during the study
Exclusion Criteria:
Branched Chain Amino Acids, 10g BID x 12 weeks
Dietary Supplement: Branched Chain Amino Acids
Branched Chain Amino Acids, 20g BID x 12 weeks
Dietary Supplement: Branched Chain Amino Acids
Branched Chain Amino Acids, 30g BID x 12 weeks
Dietary Supplement: Branched Chain Amino Acids
Protein without BCAA, 10g BID x 12 weeks
Dietary Supplement: Protein Control
Drug pages: LeucineStudies of LeucineLeucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IsoleucineStudies of IsoleucineIsoleucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ValineStudies of ValineValine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
Also known as: BCAA-20
Drug pages: LeucineStudies of LeucineLeucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IsoleucineStudies of IsoleucineIsoleucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ValineStudies of ValineValine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
Also known as: BCAA-40
Drug pages: LeucineStudies of LeucineLeucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IsoleucineStudies of IsoleucineIsoleucine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ValineStudies of ValineValine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
Also known as: BCAA-60
Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
Patient Satisfaction With Overall Study Process
Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.
Time frame: 12 weeks
Monitoring of Side Effects Scale (MOSES)
Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Time frame: 4 weeks
Change in Monitoring of Side Effects Scale (MOSES)
Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Time frame: 8 weeks
Change in Monitoring of Side Effects Scale (MOSES)
Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Time frame: 12 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Time frame: 4 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Time frame: 8 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Time frame: 12 weeks
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Time frame: Year 1
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Time frame: Year 2
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Time frame: Year 3
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Time frame: Year 4
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Time frame: Year 1
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Time frame: Year 2
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Time frame: Year 3
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Time frame: Year 4
Study Drug Adherence by Serum
Proportion of study drug consumed assessed by serum of BCAA.
Time frame: 12 weeks
Study Drug Adherence by Sleep Diary
Proportion of study drug consumed assessed by sleep diary.
Time frame: 12 weeks
Study Drug Adherence by Drug Accounting
Proportion of study drug consumed within each timepoint assessed by drug accounting.
Time frame: 12 weeks
Actiwatch Adherence
Proportion of days with actiwatch worn
Time frame: 12 weeks
Screen Failures
Number of enrolled participants who were later found ineligible
Time frame: From enrollment to randomization (~4 weeks)
Incidence of Non-Participation
Reason for not participating after initial contact and before consent as descriptive percent
Time frame: From first contact to declining (~1 week)
Retention by Arm
Number of participants retained by study arm
Time frame: From randomization to study completion (~12 weeks)
Change in Insomnia Severity Index (ISI) From Baseline
Change in Insomnia Severity Index (ISI) range: 0-28, higher means worse sleep
Time frame: 12 weeks
| Milestone | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Started | 40 | 37 | 45 | 37 |
| Completed | 24 | 14 | 18 | 24 |
| Not completed | 16 | 23 | 27 | 13 |
| Withdrew: Lost to follow-up | 7 | 9 | 8 | 4 |
| Withdrew: Withdrawal by subject | 9 | 14 | 19 | 9 |
Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.
| Units on a Scale | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Patient Satisfaction With Overall Study Process | 4.2 ± 1.0 | 4.2 ± 1.0 | 4.5 ± 0.7 | 4.5 ± 0.8 |
Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
| Units on a Scale | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Monitoring of Side Effects Scale (MOSES) | 7.2 ± 10.9 | 9.0 ± 18.7 | 8.2 ± 8.9 | 7.3 ± 13.4 |
Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
| Units on a Scale | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Change in Monitoring of Side Effects Scale (MOSES) | -1.3 ± 14.4 | -4.3 ± 14.4 | -2.3 ± 9.7 | -3.2 ± 15.4 |
Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
| Units on a Scale | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Change in Monitoring of Side Effects Scale (MOSES) | 2.3 ± 16.8 | -1.4 ± 13.3 | -0.4 ± 23.6 | -2.6 ± 17 |
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Side Effects | 0 | 1 | 0 | 0 |
| Bad Taste | 0 | 0 | 0 | 0 |
| Inconvenience | 0 | 0 | 0 | 0 |
| Trouble Remembering | 0 | 1 | 1 | 0 |
| No Time | 0 | 0 | 0 | 0 |
| Did not feel better | 0 | 0 | 0 | 0 |
| Other | 1 | 0 | 1 | 0 |
| No reason provided | 24 | 15 | 17 | 28 |
| Multiple Selected | 1 | 2 | 4 | 1 |
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Side Effects | 0 | 0 | 2 | 1 |
| Bad Taste | 0 | 0 | 0 | 0 |
| Inconvenience | 0 | 0 | 0 | 1 |
| Trouble Remembering | 0 | 1 | 1 | 0 |
| No Time | 0 | 0 | 0 | 0 |
| Did not feel better | 0 | 0 | 0 | 0 |
| Other | 2 | 1 | 1 | 1 |
| No reason provided | 23 | 9 | 11 | 16 |
| Multiple Selected | 1 | 3 | 3 | 2 |
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Side Effects | 0 | 0 | 0 | 0 |
| Bad Taste | 1 | 2 | 4 | 9 |
| Inconvenience | 2 | 0 | 1 | 0 |
| Trouble Remembering | 0 | 0 | 0 | 1 |
| No Time | 0 | 0 | 0 | 0 |
| Did not feel better | 2 | 1 | 0 | 0 |
| Other | 2 | 0 | 0 | 2 |
| No reason provided | 3 | 2 | 0 | 2 |
| Multiple Selected | 18 | 18 | 18 | 11 |
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
| Participants | Prospective Participant Pool |
|---|---|
| VA Flyer | 9 |
| Other | 4 |
| Research Match | 3 |
| National Alliance on Mental Illness | 2 |
| Study Referral | 6 |
| ClinicalTrials.gov | 1 |
| Radio | 11 |
| Sleep Clinic | 5 |
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
| Participants | Prospective Participant Pool |
|---|---|
| VA Flyer | 63 |
| Other | 7 |
| Research Match | 28 |
| Study Referral | 43 |
| ClinicalTrials.gov | 1 |
| Sleep Clinic | 1 |
| TROOPS | 7 |
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
| Participants | Prospective Participant Pool |
|---|---|
| VA Flyer | 77 |
| Other | 10 |
| Research Match | 9 |
| Study Referral | 87 |
| Sleep Clinic | 1 |
| TROOPS | 26 |
| Lab Website | 1 |
| Repository | 18 |
| Newspaper | 2 |
| NWM Advertisment | 6 |
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
| Participants | Prospective Participant Pool |
|---|---|
| VA Flyer | 52 |
| Other | 19 |
| Research Match | 7 |
| Study Referral | 2 |
| TROOPS | 14 |
| Repository | 14 |
| NWM Ad | 9 |
Number of subjects randomized of those eligible as descriptive percent
| Participants | Eligible Participants |
|---|---|
| Recruitment | 13 |
Number of subjects randomized of those eligible as descriptive percent
| Participants | Eligible Participants |
|---|---|
| Recruitment | 37 |
Number of subjects randomized of those eligible as descriptive percent
| Participants | Eligible Participants |
|---|---|
| Recruitment | 93 |
Number of subjects randomized of those eligible as descriptive percent
| Participants | Eligible Participants |
|---|---|
| Recruitment | 16 |
Proportion of study drug consumed assessed by serum of BCAA.
No measurements were reported for this outcome.
Proportion of study drug consumed assessed by sleep diary.
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| 76-100% | 23 | 13 | 13 | 22 |
| 51-75% | 4 | 5 | 7 | 2 |
| 25-50% | 4 | 6 | 5 | 5 |
| 0-24% | 3 | 3 | 11 | 3 |
| Missing | 6 | 10 | 9 | 5 |
Proportion of study drug consumed within each timepoint assessed by drug accounting.
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| 76-100% | 14 | 9 | 9 | 18 |
| 51-75% | 6 | 2 | 7 | 5 |
| 25-50% | 4 | 9 | 7 | 5 |
| 0-24% | 5 | 3 | 8 | 3 |
| Missing | 11 | 14 | 14 | 6 |
Proportion of days with actiwatch worn
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| 76-100% | 1 | 1 | 1 | 7 |
| 51-75% | 7 | 3 | 6 | 6 |
| 25-50% | 11 | 7 | 12 | 9 |
| 0-24% | 4 | 11 | 8 | 4 |
| Missing/Not Collected | 17 | 15 | 18 | 11 |
Change in Insomnia Severity Index (ISI) range: 0-28, higher means worse sleep
| Units on a Scale | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Change in Insomnia Severity Index (ISI) From Baseline | -2.3 ± 4.3 | -3.4 ± 6.2 | -0.9 ± 5.4 | -1.9 ± 5.3 |
Number of enrolled participants who were later found ineligible
| Participants | Consented Participants |
|---|---|
| Screen Failures | 8 |
Reason for not participating after initial contact and before consent as descriptive percent
| Participants | Individuals Who Declined |
|---|---|
| BCAA Consumption Concerns | 2 |
| No Reason | 18 |
| Time Commitment | 12 |
| Sleep Equipment | 1 |
| Personal Health Concerns | 2 |
Number of participants retained by study arm
| Participants | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| Retention by Arm | 24 | 14 | 18 | 24 |
Collected over from enrollment until end of follow-up, up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCAA 20g/Daily | 0/40 (0%) | 1/40 (2.5%) | 14/40 (35%) |
| BCAA 40g/Daily | 0/37 (0%) | 0/37 (0%) | 8/37 (21.6%) |
| BCAA 60g/Daily | 0/45 (0%) | 1/45 (2.2%) | 14/45 (31.1%) |
| Placebo 20g/Daily | 0/37 (0%) | 0/37 (0%) | 10/37 (27%) |
| Event | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| GallstonesGastrointestinal disorders | 1/40 | 0/37 | 0/45 | 0/37 |
| Renal FailureRenal and urinary disorders | 0/40 | 0/37 | 1/45 | 0/37 |
| Event | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 2/40 | 3/37 | 6/45 | 3/37 |
| NauseaGastrointestinal disorders | 3/40 | 2/37 | 2/45 | 3/37 |
| StomachacheGastrointestinal disorders | 3/40 | 0/37 | 2/45 | 1/37 |
| Headache/MigraineGeneral disorders | 2/40 | 1/37 | 0/45 | 0/37 |
| DiarrheaGastrointestinal disorders | 0/40 | 1/37 | 2/45 | 1/37 |
| Erectile dysfunctionReproductive system and breast disorders | 0/40 | 0/37 | 0/45 | 1/37 |
| Lung InfectionRespiratory, thoracic and mediastinal disorders | 0/40 | 0/37 | 0/45 | 1/37 |
| Ear infectionEar and labyrinth disorders | 0/40 | 1/37 | 0/45 | 0/37 |
| Product QualityProduct Issues | 1/40 | 0/37 | 0/45 | 0/37 |
| RashGeneral disorders | 1/40 | 0/37 | 0/45 | 0/37 |
Represents the number of participants randomized to each arm.
| Age, Continuous(years) | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily | Total |
|---|---|---|---|---|---|
| Mean | 47.6 ± 9.4 | 48.0 ± 10.1 | 50.8 ± 9.5 | 50.0 ± 10.0 | 49.3 ± 9.8 |
| Sex: Female, Male(Participants) | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily | Total |
|---|---|---|---|---|---|
| Female | 10 | 11 | 11 | 10 | 42 |
| Male | 30 | 26 | 34 | 27 | 117 |
| Race/Ethnicity, Customized(Participants) | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily | Total |
|---|---|---|---|---|---|
| Race/Ethnicity — American Indian/Alaskan | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity — Asian | 1 | 1 | 1 | 0 | 3 |
| Race/Ethnicity — Black or African American | 3 | 5 | 4 | 0 | 12 |
| Race/Ethnicity — Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity — Hispanic | 4 | 3 | 1 | 1 | 9 |
| Race/Ethnicity — White | 26 | 24 | 35 | 30 | 115 |
| Race/Ethnicity — Mixed | 6 | 3 | 3 | 4 | 16 |
| Race/Ethnicity — Unknown | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity — Other | 0 | 00 | 1 | 2 | 3 |
| Insomnia Severity Index (ISI)(Units on a Scale) | BCAA 20g/Daily | BCAA 40g/Daily | BCAA 60g/Daily | Placebo 20g/Daily | Total |
|---|---|---|---|---|---|
| Mean | 14.1 ± 5.8 | 14 ± 6.0 | 13.3 ± 5.9 | 13.2 ± 5.7 | 13.6 ± 5.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — A limited dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying any individual whose data are included in the dataset.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 6 months after the resulting publication
Access criteria: Final datasets will be maintained locally until institutional resources become available for public access to data sets. Limited de-identified data sets will be made available on a case-by-case basis in response to specific user requests that meet criteria specified above.
Ran from Jun 2021 to primary completion in Sep 2025, 51 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 51 months is above that.
Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Leucine · Isoleucine · Valine
VA Office of Research and Development →